Introduction
Recent advances in recombinant adeno-associated virus (rAAV) vector technology have facilitated the production of high purity, high titer wild-type free vector stocks. 1, 2 Such purified rAAV efficiently delivers genes to target tissues with much reduced toxicity compared with most other viral vector systems. 3 In addition, a range of novel promoters have been isolated and characterized that confer sustained high level constitutive and tissue specific expression. 4, 5 These advances have lead to promising applications for rAAV including novel therapies for disease models in rodents 6, 7 and nonhuman primates. 8, 9 Translation to the clinic for rAAV is currently limited to diseases in which regulation of the transgenic protein is not critical, for example factor IX in hemophilia, or CFTR in cystic fibrosis. However, for successful translation of rAAV for many other conditions, particularly when delivering neurotrophic factors, cell survival transcription factors or anti-apoptotic genes, tight regulation, and specifically the ability to 'switch off' gene expression on demand is a critical safety valve. Several regulatable gene expression systems have been developed, such as the tetracyclineresponsive and rapamycin-inducible systems, which have been shown to facilitate dose-dependent regulation of gene expression in mammalian cells by the addition or removal of an inducer. 10, 11 Correspondence: MJ The tetracycline-responsive system is an ideal system for tightly regulated gene expression mediated by rAAV. There are no known pleiotropic effects as the system is entirely prokaryotic and doxycycline (an analog of tetracycline), which is used to induce or repress gene expression, can be used at doses far lower than those used clinically as an antibiotic. Since rAAV has a size constraint of approximately 5 kb, the tet responsive cassette shows great promise for use with rAAV, as it is relatively small compared with other regulated systems and may allow for rAAV-mediated transfer of larger transgenes within a single vector.
In the present study, we have optimized an autoregulated, bidirectional rAAV-based construct for in vitro and in vivo regulation of gene expression by doxycycline. We minimized the size of the cassette to allow transgenes of up to approximately 2 kb to be readily packaged and we demonstrate rAAV-mediated transfer of reporter genes which can be regulated in vitro and in vivo with extremely low basal expression.
Results

Construction and characterization of plasmids
A bidirectional, autoregulatory tetracycline responsive expression cassette (pBIG3r) 12 contains tTA under control of the minimal tk promoter and the transgene under control of the minimal CMV promoter flanking a central tetO heptamer (Figure 1 ). The main advantage of this cassette is that it directs a low level of expression when turned off, yet leads rapidly to a high level of induction when turned on, hence facilitating a low level of basal expression, yet a high level of induced expression via a positive feedback system. Transcriptional 'squelching', which occurs when an excess of the transactivator titrates out the cellular transcriptional machinery, is considerably decreased when the weak minimal tk promoter is used in place of the minimal CMV promoter. 12 Our aim was to modify this plasmid for use with rAAV by reducing the size and basal background expression.
Our first goal was to decrease the size of the expression cassette to facilitate the insertion of larger transgenes into an AAV genome which has a packaging limit of approximately 5 kb. Various plasmids containing the luciferase reporter gene were generated ( Figure 1 ) and after transient transfection into HEK 293 cells, luciferase assays were performed on the cell lysates. First, the two chimeric introns present in pBIG3r were systematically removed to determine whether their presence was critical for expression. Removal of the chimeric intron between the minimal CMV promoter and luciferase (pBIG3r.2) resulted in no loss of luciferase expression, however removal of both introns (pBIG3r.3) resulted in a significant decrease in luciferase expression to 25% of the level obtained with pBIG3r, (P = 0.05; Student's t test) ( Figure  2 ). To reduce the size of the cassette further, the bGH polyA at the 3Ј end of luciferase was replaced with the shorter SV40 late polyA (pBIG3r.4). This had no effect on the maximum level of expression however, surprisingly, basal expression in the presence of doxycycline was significantly reduced (P = 0.03; Student's t test) which increased repression from four-to 20-fold. Replacement of the second bGH pA with SV40 late (pBIG3r.5) did not further increase the repression (Figure 2) .
A plasmid lacking the intron between the minimal CMV promoter and luciferase and the SV40 late polyA in place of the bGH polyA (pBIG3r.6) showed decreased basal expression compared with pBIG3r (P = 0.006) which increased repression from four-to 21-fold. When compared with the strong constitutive elongation factor (EF) promoter (EF-luc-WPRE), the level of gene expression driven by the autoregulatory system was determined to be more than six-fold higher (Figure 2 ). In addition to increasing the repressibility of the system, these modifications decreased the size of the cassette by 273 bp. To determine whether the overall level of expression could be increased, the woodchuck post-transcriptional regulatory element (WPRE) was inserted into pBIG3r.6 at the 5Ј end of luciferase. WPRE has been shown to increase the level of gene expression by assisting RNA transport. 13 Addition of WPRE increased maximum luciferase expression approximately two-fold compared with pBIG3r.6 (P = 0.0001), although the basal level of expression was also increased (P = 0.0001), leading to 17-fold repression ( Figure 2 ). As the addition of WPRE increased the size of the cassette considerably, the use of this element was not further pursued in this study, however, the presence of WPRE may be extremely useful for the AAV-based regulation of small transgenes or within other non-AAV-based systems in which packaging size is not critical.
Construction and characterization of doxycyclineregulated AAV plasmids
In light of the high level of repression and decreased size of pBIG3r.6, this construct was subcloned into the pAAV backbone between the inverted terminal repeats (AAV/BIG3r.6) ( Figure 3 ). Addition of the ITRs significantly increased the level of basal and induced luciferase expression (P = 0.001 and P = 0.0001, respectively) ( Figure 4 ). The AAV ITRs have been shown to contain promoter activity.
14 If the increase in expression was mediated by elements in the ITRs, we hypothesized that the addition of insulator elements may block this promoter effect. Due to the packaging size constraints of an AAV vector, insulator sequences need to be very short, therefore we chose a tandem copy of a 42 bp portion of the chicken β-globin insulator that has been demonstrated to provide enhancer blocking activity in an erythroleukemia cell line. 15 Tandem copies of the 42 bp fragment were inserted immediately internally to both ITRs (AAV/(ins)BIG3r.6). We found there was a decrease in the induced 'on' level of expression (P = 0.03), and also a possible decrease in the basal expression (P = 0.06). This caused a slight increase in repressibility, however the insulators did not fully repress the enhancement caused by the ITRs, suggesting that they are only partially functional in vitro.
In the context of an autoregulatory cassette, the VP16 activation domain has been associated with transcriptional squelching and growth arrest. 16 Replacement of full length VP16 with a triplet of a 12 amino acid minimal activation domain of VP16 (VP16 triplet) has been shown to remove unnecessary interactions with a variety of transcription factors 17 and furthermore, the VP16 triplet has been previously shown to provide 98% of the activity of full length VP16 using a two plasmid Tet On system. 17 Utilization of the VP16 triplet, in concert with the weak minimal tk promoter, should remove the possibility of Gene Therapy squelching caused by a high level of VP16. We investigated whether replacement of the full length VP16 activation domain with the VP16 triplet would be fully functional in the context of this regulatable system. We found that the VP16 triplet showed the same level of expression and repressibility as the full length VP16 (AAV(ins) BIG3r.9) (Figure 4 ). Furthermore, a secondary advantage was that 276 bp was removed by replacing full length VP16 with the VP16 triplet.
The presence of a nuclear localization signal (NLS) has been demonstrated to increase the level of inducibility of a doxcycline regulated cassette, 12 however it has also been found to increase basal expression. 18 We compared the BIG3r.9 (NLS containing) construct with one in which the NLS was removed (BIG3r.10) and found a significant decrease in basal leakiness (P = 0.006) on removal of the NLS, which lead to an increase in inducibility from sixto 17-fold after removal of the NLS (Figure 4 ).
Doxycycline regulation of AAV-mediated GFP expression in vitro
Recombinant AAV vectors containing the three most promising cassettes, ie BIG3r.6, (ins)BIG3r.6 and (ins)BIG3r.10 were packaged and purified using heparin affinity columns. The EGFP reporter was used for visualization of transduced cells and for ease of quantitation. Analysis of the level of repression by counting EGFP cells was determined to be comparable to that of measuring luciferase activity as plasmid transfection of plasmids expressing EGFP gave the same level of repression as that of plasmids expressing luciferase (data not shown).
HEK293 cells were infected with approximately 1.6 × 10 8 genomic particles of each rAAV vector. The level of repressibility was increased by approximately five-fold compared with plasmid transfections for all three vectors ( Figure 5 ). The rAAV/(ins)BIG3r.6 vector was slightly less leaky than the noninsulator containing rAAV/BIG3r.6, although not to a significant level ( Figure  5 ). Removal of the NLS (rAAV/(ins)BIG3r.10) resulted in a decrease in expression of approximately 40% in the 'on' state, however the level of basal expression was significantly reduced when compared with the rAAV/BIG3r.6 and rAAV/(ins)BIG3r.6 vectors (P = 0.0001 and P = 0.002, respectively). 
Doxycycline regulation of rAAV-mediated EGFP expression in the rat striatum
We then determined whether transfer of rAAV vectors into the rat brain would lead to tight regulation in vivo. 3 × 10 7 genomic particles of each rAAV were infused stereotactically into the rat striatum. The striatum was chosen as a high level of sustained rAAV transduction has been demonstrated in this brain area 19 and the relatively homogenous intrinsic cell population allows for quantitation of EGFP-expressing cells. For all three vectors, hundreds of EGFP-positive cells were seen surrounding the injection site at 4 weeks after infusion in the absence of doxycycline ( Figure 6 ). In contrast, doxycycline-treated rats had a striatum essentially devoid of EGFP-positive cells for all three vectors, with careful analysis of sections throughout the striatum revealing very few transduced cells (and in the case of AAV/(ins) vectors only one or two) which were immediately adjacent to the needle tract. The morphology of all the transduced cells was characteristic of that of neurons as we have previously reported using constitutive promoters. 19 AAV/BIG3r.6 showed the highest level of expression, however this cassette displayed a small amount of basal leakiness leading to 49-fold repression (Figure 7 ). Upon addition of insulators (AAV/(ins)BIG3r.6), the maximal level of expression in the 'on' state was not altered significantly from AAV/BIG3r.6, but the basal leakiness was significantly reduced (P = 0.047), which facilitated an increase in repression to 204-fold. In agreement with that observed in vitro, the expression driven from AAV/(ins)BIG3r.10 (with the NLS removed) was approximately half as much as that of AAV/(ins)BIG3r.6.
Expression of both EGFP and tTA was not associated with an inflammatory response. Immunocytochemistry
Figure 6 rAAV-mediated doxycycline-responsive EGFP expression in the rat striatum. Rat striatum 4 weeks after microinjection of rAAV visualized by DAB detection of anti-GFP antibody. (a, c, e) Sections from animals without doxycycline; (b, d, f) sections from animals given doxycycline. (a, b) AAV/BIG3r.6; (c, d) AAV/(ins)BIG3r.6; (e, f) AAV/(ins)BIG3r.10. Arrows indicate needle tracts. The original magnification was ×100.
Figure 7 Analysis of rAAV-mediated, doxycycline-responsive EGFP expression in vivo. Four weeks after rAAV/EGFP vectors were microinjected into the rat striatum, EGFP-expressing cells were counted from animals given 0 or 300 g/ml doxycycline. Each bar represents mean and s.e.m., n = 3 animals. The fold difference between repressed and unrepressed expression is indicated above the bars for each construct.
using antibodies directed against CD8 cytotoxic T cells and CD4 helper T cells was performed. A small number of helper T cells were detected along the needle tract (Figure 8a, b) , which was attributed to injury caused by the surgical procedure itself as it was restricted to the needle tract and was found in both the absence and presence of EGFP expression. We have previously observed the same phenomenon with sham or PBS injections (data not shown). No cytotoxic T cells were detected in any brain sections (Figure 8c, d) .
Discussion
The use of doxycycline-regulated cassettes in the setting of gene transfer using rAAV fulfills several requirements. The vectors should be nontoxic, nonimmunogenic and turned on and off in a dose-responsive manner. In addition, an ideal system should also be tightly regulated in vivo. Previous studies have been plagued by leaky expression in the basal state. 20, 21 An elegant system has recently been reported in which a transcriptional silencer binds rtTA in the absence of doxycycline to actively repress expression. 22 The use of this type of system may, however, be limited for use with rAAV as it involves either very large expression cassettes or the use of up to three separate plasmids. In an rAAV-based system the expression cassette should be as small as possible so as not to preclude packaging of larger transgenes. Although exciting developments on the use of introns containing trans-splicing vectors has theoretically extended the packaging limits of AAV, [23] [24] [25] such systems, with their dependence on head to tail concatemerization and 'double hits' of different vectors, are relatively inefficient. We believe the ideal regulatory system would be one in which all components were contained in one vector genome thus requiring a cell to be transduced with only one vector rather than two or three. In this study, we have modified Gene Therapy a bidirectional, autoregulatory, doxycycline-regulated plasmid specifically for use with rAAV.
We decreased the size of the cassette by approximately 600 bp compared with the original pBIG3r cassette by removing a nonessential intron and replacing the full length VP16 with three 11 amino acid minimal acidic domains of VP16. We also determined that the incorporation of the synthetic intron between the minimal tk promoter and tTA was crucial for the optimum level of expression which was over six times higher in vitro than the constitutive EF promoter.
Insertion of the cassette into an AAV backbone caused an increase in maximum expression, but also a decrease in the repressibility, presumably due to the enhancer elements present within the ITRs. Insertion of insulators to isolate the ITRs from the regulatory cassette only partially ameliorated the leakiness in vitro. This may suggest that either the insulators are not strong enough to prevent ITRs from interaction with the tTA and minimal promoter driving the transgene (luciferase) expression, or that all the proteins required for the full activity of the insulators may not be present in HEK 293 cells. The repressibility of cassette was, however, increased dramatically by removal of the NLS from tTA. This is in agreement with findings that the presence of an NLS increases background expression by altering the binding affinity to tetO. 18 Our bidirectional system was found to be appropriately expressed and regulated when packaged into a rAAV vector and used to transduce HEK 293 cells in vitro. We measured a 100-fold repressibility in the presence of doxycycline which was a 20-fold higher increase in repressibility compared with the corresponding plasmid in transient transfection. The intrinsically high basal level of expression from transient plasmid transfection is thought to be due to the absence of repressive chromatin effects. 22 Integrated copies of AAV may be regulated in a manner similar to that of a stably transfected cell line or transgenic mouse, both of which, when in a chromatin environment, can facilitate very tight regulation. 10, 26 AAV transduction of the rat striatum led to very tight regulation of EGFP expression. In comparison to the hundreds of EGFP-positive neurons detected when maximally activated, only a few EGFP-positive cells in any one animal were detected in the whole striatum in the presence of doxycyline. Moreover, repressibility rose dramatically from 49-to 204-fold on the addition of insulators. These results suggest that although they may be only partially functional in vitro, the insulators may act more effectively in vivo to limit interactions between the ITRs and the expression cassette.
In summary, we have developed a doxycycline-responsive system that promotes tight regulation of an rAAVtransferred reporter gene in the rat CNS. We believe this system is ideal for AAV-based applications due to its small size and almost undetectable repressed basal expression in vivo.
Materials and methods
Cells HEK 293 cells were maintained in a humidified 5% CO 2 incubator in DMEM supplemented with 10% FCS, 25 U/ml penicillin, 25 g/ml streptomycin, 1 mm sodium pyruvate and 0.1 mm non-essential amino acids (all from GibcoBRL, Carlsbad, CA, USA). Cells were split every 3 days using standard techniques. To create AAV/BIG3r.6, the BIG3r.6 fragment was removed from pBIG3r.6 with PvuII/SalI and inserted into Asp718 (blunt)/SalI of the pAAV backbone. Tandem copies of FII β-globin insulators were inserted into the pAAV backbone in two places: immediately downstream of the 5ЈITR into KpnI/SacI and immediately upstream of the 3ЈITR into Acc65I/StuI to create AAV/(ins)BIG3r.6. AAV/(ins)BIG3r.9 was created by insertion of an XbaI (blunt)/BamHI digested 750 bp tTA-VP16 triplet fragment from ptTA2 (Clontech, Palo Alto, CA, USA) into XbaI/ApaI (blunt) of AAV/(ins)BIG3r.6 which replaced the full length VP16 with the VP16 triplet. To remove the NLS from AAV/(ins)BIG3r.9, the PCR primers noNLStop 5' CTGGAACAGTAGATCTGGCCATACAC 3' and noNLSbot 5' TCCGTCTAGACATGGTCGAATTAATTC 3' were used to amplify a 129 bp fragment of the beginning of tTA with no NLS. This was digested with XbaI/BglII and inserted into XbaI/BglII of AAV/(ins)BIG3r.9 to create AAV/(ins)BIG3r.10. This plasmid was sequenced to verify that no errors had been incorporated. The luciferase reporter gene was subcloned into the pBIG vectors by digesting them with BamHI/EcoRV and inserting a BglII/XbaI fragment from pGL3 enhancer (Promega, Madison, WI, USA) which contained the luciferase gene. EGFP was subcloned into the AAV/BIG plasmids by digesting them with BamHI/EcoRV and inserting a BamHI/SacI fragment from pIRES/EGFP (Clontech) which contained the EGFP gene.
Construction of plasmids
Plasmid transfections
HEK 293 cells were plated out at a density of 5 × 10 4 cells/cm 2 on to a 24-well plate, 24 h before transfection. The media was changed from DMEM to IMDM (+ 5% FCS) (containing 2 g/ml doxycycline if required) 2 h before transfection. 4.5 g DNA, 120 l 2.5 m CaCl 2 and 880 l of H 2 O were combined and vortexed on addition of 1 ml of 2 × HEBS solution (50 mm HEPES, 280 mm NaCl, 1.5 mm Na 2 HPO 4 , pH 7.05). 100 l of the CaP0 4 precipitate was added to each well and mixed gently. Six hours after transfection the media was changed back to DMEM (containing 2 g/ml doxycyline when required).
Luciferase assays
Forty hours after transfection the cells were harvested in 200 l lysis buffer and luciferase assays were performed according to the Promega luciferase assay protocol and measured on a Wallac Jet luminescence counter. Total protein was measured using the Bradford protein assay (BioRad, Hercules, CA, USA) and luciferase activity/g protein was calculated. A standard curve was initially performed to ensure readings were linear. Duplicate or triplicate samples were measured for each experiment and each assay was performed independently three times.
Packaging of recombinant AAV vectors AAV vectors were packaged using the pDG helper plasmid and purified by heparin affinity chromatography. 1 Genomic titers were calculated by real-time PCR with the ABI 7700 Prism Sequence Detector System using primers designed to the bGH polyA. The primers were: bGHup 5ЈTCGACTGTGCCTCTAGTTGCC 3Ј bGHlo 5ЈGAAAG GACAGTGGGAGTGGC 3Ј.
rAAV transduction of 293 cells HEK 293 cells were plated out at a density of 1 × 10 5 cells/well on to a 24-well plate, 24 h before addition of 10 l (1.6 × 10 8 genomic particles) of virus in 100 l DMEM per well. Two g/ml doxycyline was added per well when required. Forty-eight hours after addition of vector, EGFP-positive cells were visualized at 488 nm using a Leica UV microscope.
rAAV vector administration
The experiments were carried out at the University of Auckland in accordance with the guidelines for animal care and protocols that were approved by the University of Auckland Animal Ethics Committee. Male Wistar rats (250-300 g) were anesthetized with Nembutal (90 mg/kg). AAV vectors were injected stereotactically into the right hemisphere of the mid striatum (co-ordinates: AP +0.5, ML -3.0, DV -6.0, from bregma) with 2 l (3 × 10 7 genomic particles) of AAV vector combined with 1 l 20% mannitol in PBS. Six animals were injected with each vector then divided into two groups, one group received 300 g/ml doxycyline and 1% sucrose in their drinking water, and a second group received only 1% sucrose.
Immunohistochemistry
Four weeks after vector infusion, animals were perfused with 4% paraformaldehyde in 0.1 m phosphate buffer, pH 7.4. After being immersed in fixative overnight, brains were cryoprotected in 30% sucrose in 1 × PBS. Cryostatcut sections 40 m in thickness were rinsed in 1 × PBS containing 0.2% Triton X-100 before being incubated in 1% H 2 O 2 in 50% methanol for 20 min. Sections were rinsed in PBS-triton then incubated overnight at room temperature with antibodies against GFP (Abcam, Cambridge, UK; dilution 1:3000), T cell helper/ macrophages CD4 (Pharmingen, Franklin Lakes, NJ, USA; dilution 1:50), CD8 suppressor/cytotoxic T cells (Chemicon, Temecula, CA, USA; dilution 1:50). Sections were processed using standard techniques and immunoreactivity was visualized using diaminobenzidine (DAB) detection. Every second section across the injection site was processed for anti-GFP immunohistochemistry, then the number of EGFP-positive cells was doubled to give an approximation of the total number of EGFP-positive cells in the striatum.
Statistical analysis
The Student's t test (Instat 2.01) was used for all statistical analysis.
